Today we talk with Dr. Manni Mohyuddin of Kansas University Medical Center on his new paper out now in JAMA Network Open titled "Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials: A Systematic Review".

Postprotocol Therapies: doi.org/10.1001/jamanetworkopen.2021.8084

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

3.69 Reporting of Postprotocol Therapies in Multiple Myeloma with Dr. Ghulam Rehman Mohyuddin

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Patient advocates, Pharma funding, and is MRD a suitable endpoint

Patient advocates funded by Pharma

FDA makes MRD the basis for AA

Another flawed quality metric. Reviewing the NEJM paper "Beta-Blockers After Myocardial Infarction and Preserved Ejection Fraction".

Beta Blockers After Heart Attacks Don't Work

Blood based and Stool DNA colon cancer screening - Two NEJM papers

Another flawed study Keynote 564. Pembro in adjuvant RCC

3.69 Reporting of Postprotocol Therapies in Multiple Myeloma with Dr. Ghulam Rehman Mohyuddin

Download our free app to listen on your phone